OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ...

Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both ...

As an archer she uses her right foot, right shoulder, and jaw to release the arrow and gets the upper body strength from a ...

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2 A phase II trial has recently been ...

Surgeons transplanted a donor heart into a young boy, transforming him from a frail patient into a lively kid. When Sarah Lee ...

Researchers at Children's Hospital of Philadelphia (CHOP) reported long-term clinical outcomes for the largest single center cohort of individuals who underwent complex reconstructive surgery for ...

Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and ...

TOPLINE: Patients with congenital adrenal hyperplasia (CAH) receiving glucocorticoid therapy showed reduced bone mineral density (BMD), with young adult male patients particularly affected and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism ...

Neurocrine Biosciences, Inc., a leading neuroscience-focused, biopharmaceutical company, announced the US Food and Drug Administration has approved Crenessity (crinecerfont) capsules and oral solution ...

The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces excess adrenocorticotropic hormone and downstream adrenal androgen production.

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study. The FDA has approved Crenessity (crinecerfont) for ...